上海毕得医药科技股份有限公司关于股东权益变动触及1%刻度的提示性公告

Core Viewpoint - The announcement details a significant change in shareholder equity for Shanghai Bid Medical Technology Co., Ltd., indicating a reduction in shareholding by certain stakeholders, which has triggered a disclosure obligation due to the 1% threshold being crossed [1][4]. Group 1: Shareholder Information - The information disclosure obligors include Zhoushan Landan Enterprise Management Partnership (Limited Partnership), Zhoushan Xinxin Enterprise Management Partnership (Limited Partnership), and Wu Bo, who are identified as acting in concert [3][4]. - The total shareholding of the obligors decreased from 10,110,686 shares (11.12%) to 9,571,125 shares (10.53%) following the reduction of 539,561 shares, which represents 0.59% of the total share capital [4]. Group 2: Equity Change Details - The equity change occurred on November 13, 2025, when Landan Management executed a block trade to reduce its holdings [4]. - This reduction is part of a previously disclosed share reduction plan and does not trigger a mandatory tender offer [5]. Group 3: Impact and Compliance - The equity change is not expected to significantly impact the company's governance structure or ongoing operations, nor will it alter the controlling shareholder or actual controller [5]. - The reduction plan is still ongoing, and the company will ensure compliance with relevant regulations and timely disclosure of information to investors [6].